Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > ASCO 2022 > Breast Cancer > Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer

Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer

Presented by
Prof. Kevin Kalinsky, Winship Cancer Institute of Emory University, GA, USA
Conference
ASCO 2022
Trial
Phase 2, MAINTAIN
Doi
https://doi.org/10.55788/32ff9e8a
    Patients with unresectable or HR-positive/HER2-negative metastatic breast cancer who progressed on anti-oestrogen therapy (ET) plus CDK4/6 inhibitors displayed a longer progression-free survival (PFS) when switching to ET plus ribociclib compared with ET plus placebo.

    ET plus CDK4/6 inhibition is the standard-of-care for patients with HR-positive/HER2-negative metastatic breast cancer [1]. Although observational data supports switching ET while continuing CDK4/6 inhibitors after patients progress, no prospective, randomised trials have evaluated this approach [2]. The phase 2 MAINTAIN trial (NCT02632045), presented by Prof. Kevin Kalinsky (Winship Cancer Institute of Emory University, GA, USA) randomised 119 patients with HR-positive/HER2-negative metastatic breast cancer who progressed on ET plus CDK4/6 inhibitors to a switch of ET plus ribociclib or ET plus placebo [3]. PFS was the primary endpoint of this study.

    Patients who received ribociclib had a significantly longer median PFS than patients who received placebo (2.76 vs 5.29 months; HR 0.57; P=0.006). In addition, the 12-month PFS rate was approximately 3 times higher in the ribociclib arm (24.6% vs 7.4%). The results appeared to be consistent across subgroups, including the ‘prior fulvestrant/exemestane’ and ‘prior palbociclib/ribociclib’ subgroups.

    ET plus ribociclib had a manageable safety profile. Neutropenia with a grade ≥3 was more common in patients on ribociclib (38% vs 0%) but only 2 patients experienced febrile neutropenia. Furthermore, 2 patients on ribociclib had pneumonitis (1 grade 3), and 3 patients experienced grade 3 infections, compared with 0 in the placebo group.

    Interestingly, an exploratory analysis showed that patients with ESR1 wildtype mutational status may benefit more from additional ribociclib than patients with ESR1-mutated tumours (HR 0.30 vs HR 1.22). Prof. Kalinsky stressed that these were exploratory outcomes and should be interpreted as hypothesis-generating data only.

    Prof. Claudine Isaacs (Georgetown University, Washington DC, USA) responded to these results with enthusiasm and caution. “This is the first well-designed, randomised trial to assess the applicability of CDK4/6 inhibitors and switch of ET after disease progression. However, the current study is too small to deliver practice-changing data in my opinion and it remains unclear whether we need to switch both ET and CDK4/6 inhibitors. Fortunately, other phase 2 and 3 trials are underway to investigate these issues.”

    1. Hortobagyi GN, et al. N Engl J Med. 2022;386:942–950.
    2. Wander SA, et al. J Natl Compr Canc Netw. 2021;1–8.
    3. Kalinsky K, et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. LBA1004, ASCO 2022 Annual Meeting, 3‒7 June, Chicago, IL, USA.

    Copyright ©2022 Medicom Medical Publishers



    Posted on